Valuation: Evotec

Market Cap 49Cr 55Cr 46Cr 42Cr 79Cr 5.33TCr 79Cr 551.17Cr 215.67Cr 2.72TCr 206.77Cr 202.27Cr 8.72TCr P/E 2026 *
-2.17x
P/E 2027 * -6.43x
Enterprise Value 63Cr 71Cr 59Cr 54Cr 101.4Cr 6.88TCr 101.79Cr 711.19Cr 278.29Cr 3.51TCr 266.8Cr 261Cr 11TCr EV / Sales 2026 *
1.06x
EV / Sales 2027 * 0.9x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-.--% - - 55Cr
-2.59%-5.70%+50.69%+86.86% 7.06TCr
+3.23%-10.67%+6.27%+53.48% 5.1TCr
+1.56%+1.17%+8.49%+31.81% 4.81TCr
+0.39%+0.65%+31.14%+27.04% 4.28TCr
+0.87%-8.17%+293.37%+643.87% 4.07TCr
+1.24%-1.01%+10.74%+94.55% 4.03TCr
-2.13%-1.64%+8.63%+46.88% 3.06TCr
-0.46%-1.28%+42.23%+20.34% 2.82TCr
+5.32%+0.06%-5.00%-12.60% 2.44TCr
Average +1.58%-2.66%+49.62%+110.25% 4.18TCr
Weighted average by Cap. +0.57%-2.94%+51.35%+114.84%

Financials

2026 *2027 *
Net sales 60Cr 67Cr 56Cr 51Cr 96Cr 6.51TCr 96Cr 673.13Cr 263.4Cr 3.32TCr 252.52Cr 247.03Cr 11TCr 72Cr 81Cr 67Cr 61Cr 115.66Cr 7.85TCr 116.1Cr 811.17Cr 317.41Cr 4TCr 304.3Cr 297.69Cr 13TCr
Net income -22Cr -25Cr -21Cr -19Cr -35Cr -2.41TCr -36Cr -248.68Cr -97Cr -1.23TCr -93Cr -91Cr -3.93TCr -4.83Cr -5.41Cr -4.49Cr -4.08Cr -7.71Cr -522.78Cr -7.74Cr -54Cr -21Cr -266.71Cr -20Cr -20Cr -855.21Cr
Net Debt 14Cr 16Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 160.03Cr 63Cr 789.63Cr 60Cr 59Cr 2.53TCr 16Cr 18Cr 15Cr 14Cr 26Cr 1.76TCr 26Cr 181.66Cr 71Cr 896.4Cr 68Cr 67Cr 2.87TCr
Projected Income Statement - Annual - Evotec
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Ratings Surperformance© - Evotec
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.768EUR
Average target price
4.586EUR
Spread / Average Target
+65.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec